Georg Lenz
Overview
Explore the profile of Georg Lenz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
250
Citations
9401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Functional apoptosis profiling reveals vulnerabilities in T-cell large granular lymphocytic leukemia
Shumilov E, Mazzeo P, Trautmann M, Levien L, Menck K, Richter K, et al.
Ann Hematol
. 2025 Feb;
104(1):581-591.
PMID: 39912943
T-cell large granular lymphocytic leukemia (T-LGLL) is a rare hematologic neoplasm characterized by clonal expansion of CD3 + cytotoxic T lymphocytes and a highly heterogeneous clinical course. Conventional therapy primarily...
2.
Irmer B, Wlochowitz D, Krekeler C, Richter K, Chandrabalan S, Bayerlova M, et al.
Mol Oncol
. 2025 Jan;
19(3):614-634.
PMID: 39825568
The transcriptomic classification of primary colorectal cancer (CRC) into distinct consensus molecular subtypes (CMSs) is a well-described strategy for patient stratification. However, the molecular nature of CRC metastases remains poorly...
3.
Ronnacker J, Grau M, Klasmeier M, Klesse C, Baldauf H, Abert S, et al.
Blood
. 2025 Jan;
PMID: 39813679
Apolipoprotein E (APOE) has multiple functions in metabolism and immunoregulation. Its common germline variants APOE2, APOE3 and APOE4 give rise to three functionally distinct gene products. Previous studies reported yin-yang...
4.
Harris W, Cao Y, Morschhauser F, Salles G, Jiang Y, Bottos A, et al.
Leuk Lymphoma
. 2025 Jan;
1-8.
PMID: 39792708
The cell of origin (COO) classification is an expression-based tumor algorithm identifying molecular subtypes of diffuse large B-cell lymphoma (DLBCL) with distinct prognostic characteristics. Traditional immunohistochemical methods for classifying COO...
5.
Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, et al.
Blood Adv
. 2024 Dec;
PMID: 39661985
Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after at least two prior treatment lines, but real-world data is scarce....
6.
Kemper M, Elges S, Kies P, Wiebe K, Lenz G, Bleckmann A, et al.
Transl Lung Cancer Res
. 2024 Nov;
13(10):2813-2827.
PMID: 39507015
Background And Objective: The standard first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor () mutations or anaplastic lymphoma kinase () fusions is...
7.
Stelljes M, Sockel K, Floeth M, Schetelig J, Bornhauser M, Reicherts C, et al.
Bone Marrow Transplant
. 2024 Nov;
60(1):103-106.
PMID: 39500997
No abstract available.
8.
Karsten I, Shumilov E, Schmitz N, Lenz G
Br J Haematol
. 2024 Oct;
205(6):2163-2174.
PMID: 39466716
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma, accounting for ~40% of all cases in adults. Whilst approximately two-thirds of DLBCL patients can be cured by first-line...
9.
Schoefbaenker M, Gunther T, Lorentzen E, Romberg M, Hennies M, Neddermeyer R, et al.
PLoS Pathog
. 2024 Oct;
20(10):e1012624.
PMID: 39405332
Neutralising antibodies against the SARS-CoV-2 spike (S) protein are major determinants of protective immunity, though insufficient antibody responses may cause the emergence of escape mutants. We studied the humoral immune...
10.
Lenz G, Tilly H, Ziepert M, Altmann B, Herbaux C, Frontzek F, et al.
Leukemia
. 2024 Sep;
38(12):2709-2711.
PMID: 39322715
No abstract available.